Concord Biotech Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹326Cr
- −24.2% YoY
- +17.3% QoQ
- Net profit
- ₹90Cr
- −36.6% YoY
- +32.4% QoQ
- Margin
- 38%
- −6 pp YoY
- +1 pp QoQ
Guidance rank: #74 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
Concord Biotech expects strong revenue growth in FY27, likely exceeding their historical growth rate of around 18%. - There is good visibility for growth starting from Q1 and Q2 of FY27. - The company anticipates volume growth in APIs, particularly in anti-infective and oncology segments, driven by new product launches (e.g., Nystatin, Fusidic Acid). - Capacity utilization is progressively improving with Unit 1 at optimal capacity and Unit 3 around 50%, supporting growth without immediate large capex. - The manufacturing capacities across units can support peak revenue potential of approximately INR 3,000 crores. - Growth levers include new injectables facility, U.S. Concord Biotech expects strong growth in FY27, with visibility for growth starting from Q1 and Q2. - Historical growth rate around 18%; FY27 growth is expected to be slightly better than this. - Operating leverage from injectables and Stellon Biotech U.S.
From Concord Biotech Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Concord Biotech expects strong revenue growth in FY27, likely exceeding their historical growth rate of around 18%.
- There is good visibility for growth starting from Q1 and Q2 of FY27.
- The company anticipates volume growth in APIs, particularly in anti-infective and oncology segments, driven by new product launches (e.g., Nystatin, Fusidic Acid).
- Capacity utilization is progressively improving with Unit 1 at optimal capacity and Unit 3 around 50%, supporting growth without immediate large capex.
- The manufacturing capacities across units can support peak revenue potential of approximately INR 3,000 crores.
- Growth levers include new injectables facility, U.S. subsidiary Stellon Biotech, CDMO opportunities, and topical range facility.
2 more points from Concord Biotech Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Concord Biotech Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Current year capex guidance is around INR 20-30 crores, mainly for maintenance and smaller growth projects.
- No large capex expected this year unless new projects require it, e.g., additional facility for topical range planned this financial year.
- Recently commissioned facilities include soft gel facility and injectable plant; some capex spent on modifications for a large-volume innovator project.
- Next substantial capex tranche (above INR 50-100 crores) likely 2-3 years out, with any very large additions 4-5 years away.
2 more points from Concord Biotech Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Concord Biotech Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Concord Biotech has significant visibility on the orderbook for the first half of FY27.
- Inventory levels are slightly elevated but mostly linked to identified customer demand or forecasts, especially outside the Middle East.
- In the Middle East, inventory is primarily API-related due to staggered approaches caused by geopolitical challenges; formulation inventory is not held due to shelf life issues.
- Some tenders, especially in the Middle East formulations, were delayed in FY26 but remain work in progress.
- The timing issues in tender execution affected FY26 but are expected to normalize with gradual supplies in FY27.
2 more points from Concord Biotech Ltd's call on order book
Create a free account to keep reading this call
Concord Biotech Ltd — Quarterly revenue & net profit
Concord Biotech Ltd Q4 FY26 results — key figures
| ₹ Cr | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 326 | 430 | -24.2% | 278 | +17.3% |
| Operating profit (EBITDA) | 122 | 190 | -35.8% | 102 | +19.6% |
| Operating margin | 38% | 44% | -6 pp | 37% | +1 pp |
| Profit before tax | 118 | 185 | -36.2% | 90 | +31.1% |
| Net profit (PAT) | 90 | 142 | -36.6% | 68 | +32.4% |
| EPS (₹) | 4.30 | 6.78 | -36.6% | 3.24 | +32.7% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹312 Cr, net profit ₹76 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Concord Biotech's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Balaxi Pharma (Q4 FY26)
Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY
- Accretion Pharmaceuticals (Q4 FY26)
45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks
- Gujarat Themis Biosyn (Q4 FY26)
. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.
- Aptus Pharma (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Concord Biotech Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Concord Biotech Ltd Q4 FY26 results?
Concord Biotech expects strong revenue growth in FY27, likely exceeding their historical growth rate of around 18%. - There is good visibility for growth starting from Q1 and Q2 of FY27. - The company anticipates volume growth in APIs, particularly in anti-infective and oncology segments, driven by new product launches (e.g., Nystatin, Fusidic Acid). - Capacity utilization is progressively improving with Unit 1 at optimal capacity and Unit 3 around 50%, supporting growth without immediate large capex. - The manufacturing capacities across units can support peak revenue potential of approximately INR 3,000 crores. - Growth levers include new injectables facility, U.S. Concord Biotech expects strong growth in FY27, with visibility for growth starting from Q1 and Q2. - Historical growth rate around 18%; FY27 growth is expected to be slightly better than this. - Operating leverage from injectables and Stellon Biotech U.S.
What is Concord Biotech Ltd share price analysis?
Concord Biotech Ltd currently shows a neutral. The stock trades at a P/E of 51.0 with a market cap of ₹14,489 Cr. Investors should review the full earnings analysis for detailed insights.
Is Concord Biotech Ltd planning capital expenditure?
Current year capex guidance is around INR 20-30 crores, mainly for maintenance and smaller growth projects. - No large capex expected this year unless new projects require it, e.g., additional facility for topical range planned this financial year. - Recently commissioned facilities include soft gel facility and injectable plant; some capex spent on modifications for a large-volume innovator project. - Next substantial capex tranche (above INR 50-100 crores) likely 2-3 years out, with any very large additions 4-5 years away. - Existing capacities are adequate to support turnover up to INR 3,000 crores; future capex mostly for debottlenecking/maintenance or new customer-driven projects. - Strategic growth levers include expansion in injectables, CDMO through Stellon Biotech (U.S.
Keep Concord Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
